Article
Oncology
Pablo Munoz-Schuffenegger, Aisling Barry, Eshetu G. Atenafu, John Kim, James Brierley, Jolie Ringash, Anthony Brade, Robert Dinniwell, Rebecca K. S. Wong, Charles Cho, Tae Kyoung Kim, Gonzalo Sapisochin, Laura A. Dawson
Summary: This study investigated the long-term outcomes of patients with HCC and MVI treated with SBRT, showing promising results in terms of local control and overall survival. Patients who received sorafenib treatment after SBRT had longer survival, but some patients experienced adverse events like gastrointestinal bleeding.
RADIOTHERAPY AND ONCOLOGY
(2021)
Review
Oncology
Guanheng Wu, Guomin Huang, Jianwen Huang, Ligong Lu, Shaojun Peng, Yong Li, Wei Zhao
Summary: This systematic review and meta-analysis compared external beam radiation therapy modalities for hepatocellular carcinoma (HCC) with macrovascular invasion (MVI). The findings showed that particle radiotherapy (PRT) had higher overall survival (OS) and objective response rate (ORR) compared to conventional radiotherapy (CRT) and stereotactic body radiotherapy (SBRT). Combination therapy based on radiotherapy was also found to be effective in prolonging survival. PRT was associated with fewer complications than photon radiotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Hong-Ming Tsai, Meng-Zhi Han, Yih-Jyh Lin, Ting-Tsung Chang, Chiung-Yu Chen, Pin-Nan Cheng, Chiao-Hsiung Chuang, I-Chin Wu, Po-Jun Chen, Jui-Wen Kang, Yen-Cheng Chiu, Hung-Chih Chiu, Shih-Chieh Chien, Hsin-Yu Kuo
Summary: The study investigated the efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma with vascular tumor thrombosis and found that vascular response significantly correlated with longer overall survival. The high response rate of tumor thrombi to immunotherapy with PD-1 inhibitors suggests it may be a feasible treatment option for HCC patients with thrombi.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Surgery
Mengling Ji, Hao Zou, Baojun Shu, Guoping Liu, Bingyuan Zhang, Zejiang Xu, Fanfan Pang, Mengxing Cheng, Yafei Sun, Ting Du, Chuandong Sun, Chengzhan Zhu
Summary: This study analyzed the prognostic factors of hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) and demonstrated a successful case of conversion therapy in an HCC patient with portal vein tumor thrombus (PVTT). The results identified HBsAg positivity, AFP level ≥400 ng/ml, liver capsule invasion, and tumor number ≥2 as independent prognostic factors for tumor recurrence, while HBsAg positivity was an independent risk factor for overall survival.
FRONTIERS IN SURGERY
(2022)
Article
Oncology
Takashi Niizeki, Hideki Iwamoto, Tomotake Shirono, Shigeo Shimose, Masahito Nakano, Shusuke Okamura, Yu Noda, Naoki Kamachi, Suzuki Hiroyuki, Miwa Sakai, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Summary: Macrovascular invasion (MVI) is a poor prognostic factor in hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) is a promising treatment for MVI-HCC. New FP, a regimen involving fine-powder cisplatin and 5-fluorouracil suspended with lipiodol, showed superior therapeutic outcomes compared to low-dose cisplatin plus 5-fluorouracil (LFP) in treating MVI-HCC with preserved liver function. New FP is recommended as a preferred HAIC regimen for this patient population.
Article
Oncology
Huiwen Yan, Xinhui Wang, Dongdong Zhou, Peng Wang, Zhiyun Yang
Summary: This study developed and validated a dynamic nomogram including multiple risk factors associated with MVI, demonstrating good discrimination and accuracy, providing a reliable basis for clinical decision-making.
Article
Radiology, Nuclear Medicine & Medical Imaging
Joseph C. Ahn, Marie Lauzon, Michael Luu, Marc L. Friedman, Kambiz Kosari, Nicholas Nissen, Shelly C. Lu, Lewis R. Roberts, Amit G. Singal, Ju Dong Yang
Summary: In the United States, the use of TARE as a first-line therapy for HCC patients with MVI has increased, with patient characteristics, region, and medical center type affecting its utilization. TARE was associated with reduced mortality compared to systemic therapy for patients with MVI.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Kensuke Naruto, Tomokazu Kawaoka, Kenichiro Kodama, Yutaro Ogawa, Kei Amioka, Yuki Yoshikawa, Chihiro Kikukawa, Yousuke Suehiro, Kenji Yamaoka, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Takashi Nakahara, Eisuke Murakami, Atsushi Ono, Takuro Uchida, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura, Keigo Chosa, Kazuo Awai, Katsumaro Kubo, Yasushi Nagata, Kazuaki Chayama, Hiroshi Aikata
Summary: This study found that the combination of one-shot cisplatin via hepatic arterial infusion and radiation therapy could improve the prognosis of patients with hepatocellular carcinoma and macrovascular invasion. This combination therapy shows potential as a bridging therapy to systemic chemotherapy.
BMC GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Sirui Fu, Haoran Lai, Qiyang Li, Yao Liu, Jiawei Zhang, Jianwen Huang, Xiumei Chen, Chongyang Duan, Xiaoqun Li, Tao Wang, Xiaofeng He, Jianfeng Yan, Ligong Lu, Meiyan Huang
Summary: This study successfully developed a multi-task deep learning network-based model for predicting future macrovascular invasion in hepatocellular carcinoma. The best model integrated clinical/radiological factors and radiomic features, demonstrating excellent discrimination and calibration, unaffected by treatment or disease stage. Subgroup analysis revealed significant predictive value for time to macrovascular invasion and overall survival.
Article
Computer Science, Interdisciplinary Applications
Haoran Lai, Sirui Fu, Jie Zhang, Jianyun Cao, Qianjin Feng, Ligong Lu, Meiyan Huang
Summary: Macrovascular invasion (MaVI) prediction in hepatocellular carcinoma (HCC) is challenging. This study proposed a prior knowledge-aware fusion network (PKAFnet) to accurately predict MaVI in CT images. The PKAFnet showed promising performance and could incorporate clinical priori knowledge associated with HCC.
IEEE TRANSACTIONS ON MEDICAL IMAGING
(2022)
Article
Medicine, General & Internal
Maria Guarino, Alessandro Cucchetti, Giuseppina Pontillo, Fabio Farinati, Francesca Benevento, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Sacco Rodolfo, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Franco Trevisani, Edoardo G. Giannini, Filomena Morisco
Summary: In patients with hepatocellular carcinoma, the presence and extension of macrovascular invasion significantly impact survival and treatment selection, with factors such as age, symptoms, liver function, tumor size, and ascites playing crucial roles. A decision tree based on these parameters may help assess patients' prognosis and inform therapeutic decisions.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Surgery
Yi-Hao Yen, Wei-Feng Li, Kwong-Ming Kee, Chih-Chi Wang, Yu-Fan Cheng, Jing-Houng Wang, Sheng-Nan Lu, Chao-Hung Hung
Summary: This study evaluated the prevalence and extension of MaVI in HCC patients, finding that the extension of MaVI significantly affected patient survival only in those with BCLC stage C and Child-Pugh class A. In patients with BCLC stage C and Child-Pugh class B or BCLC stage D, survival was poor irrespective of MaVI status.
LANGENBECKS ARCHIVES OF SURGERY
(2022)
Review
Oncology
Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Xin-Cheng Mao, Jin-Cheng Tian, Jun-Shuai Xue, Si-Yu Tan, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li
Summary: This study aimed to evaluate the impact of macrovascular invasion (MVI) or extrahepatic spread (EHS) on the efficacy and safety of immune checkpoint inhibitors (ICIs) among hepatocellular carcinoma (HCC) patients. The findings indicated that MVI has a significant impact on efficacy, while the impact of EHS is not significant.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Immunology
Zunyi Zhang, Erlei Zhang
Summary: Hepatocellular carcinoma (HCC) is a common type of liver cancer with high mortality rate. A significant percentage of HCC patients have vascular invasion at initial diagnosis. Traditional guidelines classify HCC with vascular invasion as advanced stage, limiting surgical options. However, recent advancements in systemic and locoregional treatments have shown promising responses, leading to the proposal of a conversion therapy strategy to eventually enable surgical resection. This review summarizes the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Surgery
Giammauro Berardi, Nicola Guglielmo, Marco Colasanti, Roberto Luca Meniconi, Stefano Ferretti, Germano Mariano, Sofia Usai, Marco Angrisani, Alessandra Pecoraro, Alessio Lucarini, Camilla Gasparoli, Giuseppe Maria Ettorre
Summary: The ALPPS procedure is an extreme rescue approach for advanced hepatocellular carcinoma patients with macrovascular invasion, which can improve the prognosis of patients. However, the procedure carries high risks and patient selection is crucial.
UPDATES IN SURGERY
(2022)
Article
Gastroenterology & Hepatology
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei-Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiroyuki Suzuki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Summary: This study evaluated the impact of MAFLD on the efficacy of lenvatinib in treating HCC. The results showed that MAFLD was a beneficial factor for survival in HCC patients treated with lenvatinib, especially in those with non-viral HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Shigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Yuki Tanaka, Fujimasa Tada, Hideko Ohama, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Summary: This study evaluated the therapeutic effects and safety of ramucirumab following atezolizumab plus bevacizumab treatment. The results showed increased therapeutic effect in patients with atezolizumab plus bevacizumab failure, and patients with splenomegaly and low BMI should be monitored for ascites during ramucirumab treatment.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.
Article
Oncology
Hirona Shigyo, Hiroyuki Suzuki, Toshimitsu Tanaka, Etsuko Moriyama, Yasutaka Shimotsuura, Sachiko Nagasu, Hideki Iwamoto, Yoshito Akagi, Kenta Murotani, Takumi Kawaguchi, Keisuke Miwa
Summary: This study aimed to investigate the safety of Bevacizumab administration early after central venous (CV) port placement. The results showed that the timing of Bevacizumab initiation did not affect the frequency of complications. Therefore, it is safe to administer Bevacizumab early after CV port placement.
Article
Oncology
Hiroyuki Suzuki, Hideki Iwamoto, Takahiro Seki, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Yasuko Imamura, Takashi Niizeki, Masahito Nakano, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Miwa Sakai, Kazutoyo Morita, Masamichi Nakayama, Tomoharu Yoshizumi, Ryoko Kuromatsu, Hirohisa Yano, Yihai Cao, Hironori Koga, Takuji Torimura
Summary: This study aimed to determine the mechanisms underlying antiangiogenic TKI resistance in hepatocellular carcinoma (HCC) patients. The results showed that antiangiogenic TKI treatment increased tumor IGFBP-1 levels and promoted angiogenesis through activating the IGFBP-1-integrin alpha 5 beta 1 pathway. Inhibition of IGFBP-1 and integrin alpha 5 beta 1 could re-sensitize HCC to lenvatinib treatment.
CANCER COMMUNICATIONS
(2023)
Review
Gastroenterology & Hepatology
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Summary: Recently, there has been significant development in the treatments for unresectable hepatocellular carcinoma (HCC). Systemic chemotherapy drugs have been approved and recommended worldwide, but their effectiveness is unsatisfactory for certain tumor conditions. Hepatic arterial infusion chemotherapy (HAIC) is a traditional treatment for advanced HCC, and although its survival benefit has not been conclusively proven, accumulating clinical evidence suggests its effectiveness. A multidisciplinary therapeutic strategy combining locoregional HAIC treatment with sequential drug therapy is proposed to achieve cancer-free status through conversion therapy.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Elina En Li Cho, Chong Zhe Ang, Jingxuan Quek, Clarissa Elysia Fu, Lincoln Kai En Lim, Zane En Qi Heng, Darren Jun Hao Tan, Wen Hui Lim, Jie Ning Yong, Rebecca Zeng, Douglas Chee, Benjamin Nah, Cosmas Rinaldi Adithya Lesmana, Aung Hlaing Bwa, Khin Maung Win, Claire Faulkner, Majd B. Aboona, Mei Chin Lim, Nicholas Syn, Anand V. V. Kulkarni, Hiroyuki Suzuki, Hirokazu Takahashi, Nobuharu Tamaki, Karn Wijarnpreecha, Daniel Q. Q. Huang, Mark Muthiah, Cheng Han Ng, Rohit Loomba
Summary: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. This study determined a high prevalence of NAFLD, non-alcoholic steatohepatitis (NASH), and fibrosis in people with T2DM.
Article
Gastroenterology & Hepatology
Toshimitsu Tanaka, Hironori Koga, Hiroyuki Suzuki, Hideki Iwamoto, Takahiko Sakaue, Atsutaka Masuda, Toru Nakamura, Jun Akiba, Hirohisa Yano, Takuji Torimura, Takumi Kawaguchi
Summary: Therapeutic anti-PD-L1 antibodies promote cell proliferation by stabilizing the PD-L1-AXL complex in liver cancer cells, especially in hepatocellular carcinoma with mesenchymal components.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Hiroyuki Suzuki, Hideki Iwamoto, Toshimitsu Tanaka, Takahiko Sakaue, Yasuko Imamura, Atsutaka Masuda, Toru Nakamura, Hironori Koga, Yujin Hoshida, Takumi Kawaguchi
Summary: This study demonstrates the impact of molecular-targeted agents (MTAs) on the tumor immune microenvironment (TIME) in the treatment of advanced hepatocellular carcinoma (HCC). The results show that cabozantinib activates the innate immune system, while lenvatinib and AZD4547 alter the TIME to a hot immune state by downregulating lipid metabolism-related genes. These findings support the use of combination immunotherapies for HCC treatment.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Masatoshi Tanaka, Tomotake Shirono, Etsuko Moriyama, Yu Noda, Masahito Nakano, Hideya Suga, Ryoko Kuromatsu, Takuji Torimura, Hironori Koga, Takumi Kawaguchi
Summary: This study found that LEN combined with TIT can improve the prognosis of patients with advanced-stage HCC compared to LEN monotherapy. The use of LEN in combination with transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy showed even better results.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
